Business
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.("Searchlight"), Apotex Inc's ("Apotex") Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
About this update from Kissei Pharmaceutical Co., Ltd.
[{"type":"text","content":"TORONTO, Oct. 7, 2025 /CNW/ - Searchlight Pharma Inc.("Searchlight"), Apotex Inc's ("Apotex") Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.","length":408,"tagName":"p"},{"type":"image","alt":"Apotex Inc. Logo (CNW Group/Apotex Inc.)","displaySize":"","headline":null,"caption":"Apotex Inc. Logo (CNW Group/Apotex Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":157,"url":"https://media.zenfs.com/en/cnwgroup.com/fa74a2cd90567d5ab487c5048dba0f3e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7ONbHuO3Ju9A4ezSMZsSug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/fa74a2cd90567d5ab487c5048dba0f3e","width":400,"height":157}},"href":"https://mma.prnewswire.com/media/2790269/Apotex_Inc__Apotex_Strengthens_Commitment_to_Women_s_Health_with.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, Searchlight will lead efforts to pursue marketing authorization for linzagolix in Canada, following regulatory approval.","length":156,"tagName":"p"},{"type":"text","content":""Securing the Canadian rights to linzagolix is a meaningful step in our strategy to expand access to innovative therapies," said Allan Oberman, President and CEO, Apotex. "By adding this treatment to our portfolio, we continue to build on our commitment to addressing areas of significant need and supporting the well-being of patients."","length":357,"tagName":"p"},{"type":"text","content":""Our strategic focus is on delivering high-quality, novel therapies that meet the evolving needs of Canadian patients and complement our existing women's health portfolio," said Mark Nawacki, President, Searchlight Pharma. "Linzagolix represents a meaningful advancement in the treatment of uterine fibroids, offering a potential new option for women across the country. We're pleased to introduce this treatment option as part of our Journey of Health growth strategy and our ongoing commitment to improving patient outcomes and expanding ac...